Why the study?
Does adding nadolol to hydrochlorothiazide reduce blood pressure in patients with mild or moderate essential hypertension?
Does adding nadolol to hydrochlorothiazide reduce blood pressure in patients with mild or moderate essential hypertension?
The addition of once-daily nadolol to hydrochlorothiazide provides sustained, safe, and effective long-term blood pressure reduction in patients with mild to moderate essential hypertension.
Answers are grounded in this paper and cite their sources.
May support sustained BP reduction with nadolol added to hydrochlorothiazide; leaves open need for randomized confirmation.
After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.
No takes yet. Share an insight, caveat, or question.
El‐Mehairy et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: